Compare ADMA Biologics Inc (ADMA) vs Vistra Corp (VST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vistra Corp — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Vistra Corp trades at $154.85 (market cap $52.51B). The key difference: Vistra Corp is far larger — about 24.7× ADMA Biologics Inc's market cap, and Vistra Corp pays a 0.59% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | VST | |
|---|---|---|
Market Cap | $2.13B | $52.51B |
Sector | Health | Technology |
52-Week High | $20.38 | $217.92 |
52-Week Low | $7.60 | $134.71 |
Enterprise Value | $2.20B | $74.26B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Vistra Corp (VST) trades at $157.22, up 4.08% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but faces cash flow challenges. Revenue growth from $17.74B to $19.4B and improved net margins to 11.52% reflect operational strength, supported by AI-driven power demand catalysts and a $6.3B buyback program.
Outlook remains positive with 91% analyst buy ratings and a $230.50 price target, though technical resistance near $159 and volatile earnings pose near-term risks. Long-term growth is fueled by nuclear/renewable expansion, but investors should monitor execution on guidance and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
